Champions' PDX Models Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496

Identifying and developing targeted oncology compounds is often an arduous, costly, and time-consuming process. As the demand for effective personalized oncology therapies grows, so does the need for a more predictive model solution.

The value of Champions' Lumin Analytics database is demonstrated in our latest case study, which shows how the utilization of our PDX models in a screening and efficacy evaluation impacted the development of a novel compound, the dual BRAF-EGFR inhibitor, CEP-32496.